Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT)

Receptor-mediated radioimmunotherapy (RIT) has become an exciting field in nuclear medicine. In some indications we are succesful. Many concepts are experimental, although in use since many years [1-3], and only few, as e.g. ^{90}Y-ibritumomab tiuxetan, have gone to market but still pose a number of challenges [4].

In this context, the review by Papamichail et al. in the Greek section of the Jan-Apr 2016 issue of the HJNM on receptor-mediated RIT regimens in neuroendocrine tumors including somatostatine analogues radiolabelled with ^{111}In, ^{90}Y, ^{177}Lu, and ^{213}Bi is most timely [5]. The perception of RIT, as we think, still needs further attention and distribution as it is a valuable aid or even alternative to conventional therapy schemes. This could work if the partners, oncologists, nuclear medicine physicians, and health economists take up the discussion-together, not separately. And as peers.

The authors declare that they have no conflicts of interest

Bibliography

1. Otte A, Jermann E, Behe M et al. DOTATOC - a powerful new tool for receptor-mediated radionuclide therapy. *Eur J Nucl Med* 1997; 24: 792-5.
2. Otte A, Mueller-Brand J, Dellas S et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. *Lancet* 1998: 351: 417-8.
3. Merlo A, Hausmann O, Wasner M et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA^0-D-Phe^1-Tyr^3 octreotide (DOTATOC): a pilot study in human gliomas. *Clin Cancer Res* 1999; 5: 1025-33.
4. Otte A, Thompson SL. Practical and health economic aspects of radioimmunotherapy for the treatment of patients with non-Hodgkin's lymphoma. *Nucl Med Comm* 2006; 27: 753-6.
5. Papamichail DG, Exadaktylou PE, Chatzipavlidou VD. Neuroendocrine tumors: Peptide receptors radionuclide therapy (PRRT) (article in Greek). *Hell J Nucl Med* 2016; 19(1): 75-82.

Prof. Andreas Otte MD

Division of Biomedical Engineering, Department of Electrical Engineering and Information Technology, Offenburg University, Offenburg, Germany, Badstr. 24, D-77652 Offenburg, Germany, E-mail: andreas.otte@hs-offenburg.de

Erratum:

In the paper: "Description of the thyroid hormone resistance syndrome illustrated by such a case, which had two different carcinomas and was mistreated with iodine-131" published in the 3rd issue of HJNM for 2015, pages: 247-51, the correct legend for Figure 3 is: Thyroid papillary carcinoma of a nodule in the right thyroid lobe and for Figure 4 is: Nasal -small cell neuroendocrine carcinoma. Immunohistochemistry: CK (+), NSE (+), CgA (+), SYN (+).

Additionally, immunohistochemistry analysis necessary for the diagnosis of neuroendocrine carcinoma which was not mentioned in the above text is: CK (+), NSE (+), CgA (+), SYN (+), VIM (-), HMB45 (-), S-100(-), EMA (-), SMA (-), CK5/6 (-), P63 (-). In general the immunohistochemistry results of CK, NSE, CgA and SYN were positive.

Instructions to authors and the aim of the Journal
July 10, 2016 revision

A. The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, ***aims*** to contribute to research and education of physicians, in the field of nuclear medicine and allied sciences such as physics, dosimetry, radiation biology, computer science, radiochemistry, radiopharmacology, cell trafficking, targeting of gene expression and also to support the interests, professional and scientific, of the discipline of nuclear medicine.

B. ***General rules and submission of papers:*** a) The English section of the journal appears separately in every issue. An extended abstract in English follows every article printed in the Greek section. b) In-house corrections are done once or twice. After the in-house and the reviewers' approval, the HJNM publishes articles that have not been published elsewhere even in part. c) It is strongly suggested that the number of cases studied should not be less than 45-50 for statistical reasons. Repetitions in the text are not permitted. All acronyms should be explained the first time they appear in the text. Statements or opinions that are not related to the objective and do not derive from the findings of the article, are not permitted; especially when they favour persons or have an advertising character. d) Original, research papers, short communications and technical notes should include enough details for the readers who wish to repeat their methods and also be well understood by the readers. e) All papers may be corrected at any stage and final publication may be denied if authors are unwilling to comply with suggested corrections. f) The authors understand that their papers are available for comments or for enquiries from other colleagues and the media. g) Authors whose native language is not English are strongly advised to have their manuscripts checked by a person who has an excellent knowledge of English prior to submission. The text of the articles submitted should be written in *Times New Roman characters, size 12, line spacing 1.5 and margins 2.5cm around the text*. Capital letters and parentheses should be avoided. h) *All texts must have recent references starting from the current year backwards.* i) The names of the authors should be in the following order only: first name, middle name,

surname and degrees of all authors; under the responsibility of the corresponding author. Double publication in the English and Greek section of the journal is not allowed. j) *From the time of first sub-mission up to three years after publication in the journal, authors may be asked to provide their raw data*. k) Sometimes editors make mistakes. We would like to hear about them. l) All manuscripts are confidential *and should be of not more than 18-20 pages described as above, when first submitted excluding reviews and seminars.* m) All authors are fully responsible for the quality, the data and the integrity of their papers and also for their opinions and conclusions related to their papers.

C. *Published papers are of the following categories:* a) *Original articles* presenting and supporting new data and new theories not published before. These articles have priority. b) *Research articles*, confirming, supporting of rejecting existing data or theories. c) *Short communications;* with important results but fewer patients. d) *Seminars, reviews and short reviews* are considered as monographs and should be written by up to three authors. Multinational or epidemiological articles may be written by many authors. e) *Special articles* related to nuclear medicine, to the history of Medicine, or to medical education. f) *Distinguished lectures*. g) *Case reports* should refer to an extraordinary, prototype subject and content and be well documented. h) *Letters to the Editor* referring to papers already published are considered for publication. Letters to the Editor not referring to papers already published should include material not published before. Submission letters should be signed by all authors. All letters should have up to 1000 words. For more information about letters to the Editor please refer to other paragraphs of the present "Instructions to Authors". i) *Selected Short Contributions* may be published after permission of the Editor.

D. *Article chapters:* Every article should be divided into headed sections in the following order: a) *the title page*, which includes the name(s) of the author(s), the name(s) of their institution(s), the corresponding author and his address and 4-5 keywords. Keywords are taken from index medicus (medical subject headings). Titles and texts should be concise. Titles should express only one idea or subject and usually include no acronyms. In case, authors are more than expected for every kind of paper, the Editor may inform the corresponding author accordingly. b) The *Abstract* contains the objective upon which the article was based, the subjects or material and methods studied, the results, a brief discussion-evaluation and the conclusion of the study, all in one paragraph. c) In Introduction, authors must summarize the problem, refer briefly to previous research and explain exactly why and what they have studied. d) *Subjects, Material and Methods* should be detailed. e) *Results,* should not repeat what is presented in Tables or Figures except the title and the main result. f) *Discussion,* contains only what is related to the findings-aims of the article. No names of authors may be mentioned in Discussion, except those related to historical or exceptional events, with the year of the publication in parenthesis. References should be mentioned in brackets [ref.]. *Conclusion* should be brief, related to the findings of the study and included at the end of Discussion. g) *Acknowledgements.* h) *Bibliography* should only include works cited in the text and published or accepted for publication. Personal communications not published should be mentioned in the text only. In Bibliography, only the names of the first three authors should be mentioned adding: et al. In case the authors are four, they are all mentioned. The names of the journals or books should be in italic. Examples of references: 1. Wilson W, Davies JH, Mittel C et al. Treatment of Graves disease with iodine-131; ten years of follow up. *Hell J Nucl Med* 2013; 5: 102-12. Or: 2. Snakes DE, Murphy GI. Bone scan in breast carcinoma. In: Spiers DG, Hoffnagel AB, James A et al. Eds. *A Textbook of Radionuclides and Cancer*. 3rd edn. Lee & Febiger, London and N.Y. 2013; 410-20. For a book, give editors, publisher, the city and year of publication. For a chapter or section of a book, also give the authors, title of the section and the page numbers. For online material, please cite the URL, together with the date you accessed the website. The Editor may suggest additional and/or recent references. All Bibliography should be written in English. i) *Tables and Figures* should be easily readable and belong to the authors or be reprinted by permission, numbered in Arabic numerals and given a short title. Digital photography files should have a resolution of at least 300dpi and be at least 107mm wide. Tables should be in word format. Abbreviations within Tables should be explained with letters size 9, as footnotes. The accuracy of data etc. of the whole paper including the references and the procedure for obtaining permission for Tables and Figures is the responsibility of the authors. j) The authors and especially the corresponding author shall be responsible for false statements or failure to fulfil all requirements mentioned in the present "Instructions to Authors". Conflict of interest and financial relations should be disclosed. All papers will be checked for plagiarism, duplicate publication and text recycling.

E. *Submission of articles:* All articles may be submitted in electronic form. The Journal will communicate with the authors via email. A letter accompanying every article and signed by all authors, should state clearly that: a) All authors agree to the present Instructions to Authors. b) All authors have offered substantial contribution to conception, design, analysis, interpretation and final approval of the article version submitted for publication. c) All authors give the copyright of their article to the journal. d) The submitted article has not been and will not be submitted, even partly, for publication elsewhere. e) The article submitted has been approved by the authorities of the institution where the work was carried and that the subjects studied have given their informed consent. f) They understand that authors must take permission for their paper to be presented orally or abstracted elsewhere. g) All human studies have been performed under the rules of the 1964 Declaration of Helsinki. h) They understand that all authors must state any financial or personal relationship with people, organizations, firms etc. and declare any conflicts of interest. i) The corresponding author must state that he or she had full access to all data of the study and has final responsibility for the decision to submit the paper to HJNM. j) Reports on animals should mention that: "principles of laboratory animal care, as well as specific national laws and regulations, were followed".

F. *Other information:* For online publication, authors should communicate with the Editor. Editors cannot be held responsible for errors arising from the use of information by the authors which is published in this Journal. Views and opinions of authors do not necessarily reflect those of the Editors or of the Advisors of the Journal.

G. *Submission-corrections fee and symbolic contribution to printing expenses:* The submission corrections fee covers when needed, corrections or suggestions referring to the typical style of the Journal, syntaxis of the text, the English language, substantial suggestions, extra work of the secretariat etc. The above suggestions include: those after primary reading, after in-house assessment and also after reviewers' assessment. A submission-corrections fee of 150€-550€ may be asked for the above to be paid by the group of authors. This fee is specified by the Editor after the paper is submitted by email together with its submission letter as has previously been described. The submission-corrections fee does not mean acceptance for publication. It is important to mention that the above mentioned corrections, if needed, can be completed only with the cooperation of the authors. The Editor may not reply to the answers of the authors to the above suggestions but will inform the reviewers accordingly.

If the paper is accepted, the authors as a group may be kindly requested to pay a symbolic contribution to printing expenses of 25€ per printed page. Two typewritten pages as above are considered approximately as equal to 1 printed page. The above expenses may be partly or totally waived, after communication with the Editor. *Corresponding authors* are personally responsible for the above fee. *Corresponding authors* are supplied by one free issue of the Journal. *Off prints* are available if ordered on time. Minimum order is 20 reprints. Each reprint up to 4 pages costs 2€, postage added. *Manuscripts etc,* if sent by surface mail, will not be returned.